B. Riley lowered the firm’s price target on RadNet (RDNT) to $83 from $87 and keeps a Buy rating on the shares. The Q1 reports across the radiotherapeutics and imaging agents point to a multi-indication PET volume growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT: